CXCR4 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, it was shown that imatinib itself also increased CXCR4 expression on CML cells, indicating that treatment itself can prime tumour cells to such a state that they are more susceptible to the protective effects of MSCs.